| |
|
 |
 |
| About Inserm |
Founded in 1964, the French National Institute of Health and Medical Research (Inserm) is a public scientific and technological institute which operates under the joint authority of the French Ministry of Health and French Ministry of Research. As the only French public research institute to focus entirely on human health, in 2008 Inserm took on the responsibility for the strategic, scientific and operational coordination of biomedical research. This key role as coordinator comes naturally to Inserm thanks to the scientific quality of its teams and its ability to conduct translational research, from the laboratory to the patient’s bed.
www.inserm.fr
|
| |
 |
| About Inserm Transfert |
Founded in 2000, InsermTransfert SA is the private subsidiary of the French National Institute of the Health and Medical Research (Inserm), dedicated to technology transfer (from invention disclosure to industrial partnership). Inserm Transfert also manages European and International research projects, supports large scale projects in epidemiology and public health.
Inserm Transfert runs a 2M€/year proof of concept fund. The company also supports entrepreneurs in the biotech sector, in partnership with Inserm Transfert Initiative,
a € 39.7m life sciences seed investment company.
www.inserm-transfert.fr
|
| |
 |
| About Inserm Transfert Initiative |
Inserm Transfert Initiative is a seed-capital company that has raised €35.5 million in new funding in 2012. It focuses on providing seed capital for innovative young companies in the biomedical field. Inserm Transfert Initiative was created in 2005 through an equal partnership between four providers of finance to biotech start-ups: Inserm Transfert SA, CDCEntreprises, Natexis Venture Selection and Sofinnova Partners.
Inserm Transfert Initiative supports biotech entrepreneurs in the early stages of their companies' development.
www.it-initiative.fr
|
| |
Céline Cortot
Communication Director
Inserm Transfert
cé[email protected] |
|
 |
|
| |
|
|
|
|
| |
|
|
|
|
|
